Cristina Méndez, Spain
Pfizer Spain Vaccines UnitPoster Author Of 2 e-Posters
THE CHANGING EPIDEMIOLOGY OF INVASIVE PNEUMOCOCCAL DISEASE (IPD) IN ADULTS OF 65 YEARS OR OVER. IMPACT OF THE PAEDIATRIC PNEUMOCOCCAL VACCINATION PROGRAMME, SPAIN 2010-2017
TRENDS IN INVASIVE PNEUMOCOCCAL DISEASE (IPD) IN ADULTS OF 65 YEARS OR OVER, ITALY, 2012-2017
Author Of 2 Presentations
TRENDS IN INVASIVE PNEUMOCOCCAL DISEASE (IPD) IN ADULTS OF 65 YEARS OR OVER, ITALY, 2012-2017 (ID 1184)
Abstract
Background
The paediatric heptavalent pneumococcal conjugate vaccine (PCV7) was licensed in 2001 and added to the National Immunisation Programme (NIP) in 2005. The 13-valent conjugate vaccine (PCV13) entered the paediatric NIP in 2012. PCV13 adult vaccination started in 2012 for at-risk population in some regions and introduced in NIP in 2017 sequentially with the 23-valent polysaccharide (PPV23), used before in at-risk and older people.
Methods
Cases were reported through the European Centre for Disease Prevention and Control surveillance system. IPD serotype specific counts were aggregated into PCV13-, PCV13 non-PCV7-, 20-valent conjugate vaccine (PCV20) non-PCV13-, PPV23-, and PPV23 non-PCV13-type groups. The percentage change in annual number of cases was estimated using linear regression analysis of the log of annual number of cases.
Results
During 2012-17, there was an average annual increase of 34% for PCV20 non-PCV13- (95%CI 20.4 to 48.8; p=0.002), of 16% for PPV23- (95%CI 7.5 to 25.1; p=0.006), and of 31.5% for PPV23 non-PCV13- (95%CI 18.1 to 46.4; p=0.002)-, without significant changes in PCV13-, PCV13 non-PCV7-type groups
Conclusions
Implementation of the paediatric PCV13 programme, despite high coverage, does not appear to be associated with changes in PCV13-type IPD in adults. Reductions may be achieved with direct immunisation with PCV13 or next-generation vaccine (PCV20)
THE CHANGING EPIDEMIOLOGY OF INVASIVE PNEUMOCOCCAL DISEASE (IPD) IN ADULTS OF 65 YEARS OR OVER. IMPACT OF THE PAEDIATRIC PNEUMOCOCCAL VACCINATION PROGRAMME, SPAIN 2010-2017 (ID 470)
Abstract
Background
The paediatric heptavalent pneumococcal conjugate vaccine (PCV7) was first available in Spain in June 2001 and incorporated in the Madrid regional immunisation programme (RIP) in 2006, remaining in the private market for other regions. From mid-2010 through 2016, Spanish regions introduced the 13-valent conjugate vaccine (PCV13) in their RIPs. Adult vaccination with the 23-valent polysaccharide (PPV23) officially started in 2004, and with PCV13 in 2016 for some cohorts, without expected impact for this analysis.
Methods
Data source: cases reported through the European Centre for Disease Prevention and Control surveillance system (available online). IPD serotype specific counts were aggregated into PCV13-, PCV13 non-PCV7, 20-valent conjugate vaccine (PCV20) non-PCV13, PPV23-, and PPV23 non-PCV13-type groups. The percentage change in annual number of cases was estimated using linear regression analysis of the log of the annual number of cases.
Results
During 2010-17, an 8.1% average annual decline (95%CI -13.7 to -2.2; p=0.02) in PCV13 non-PCV7-type IPD in adults was observed. Despite vaccination, PPV23 non-PCV13-type IPD increased an average 13.2% annually (95%CI 8.6 to 17.9; p<0.001).
Conclusions
Implementation of regional paediatric PCV13 programmes in Spain has been associated with decline of PCV13-types IPD in adults ≥ 65 years. However, further reductions may only be achieved with direct immunisation